Recruiting

Testing a new medication for recurrent brain tumors with specific genetic mutations

Plain-English translation of NCT05588141 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called to treat recurrent brain tumors (gliomas) that have specific genetic mutations called IDH1 or IDH2. Early research suggests this medication may work better in patients whose tumors have these mutations. The trial will determine the best dose and whether the medication can help patients live longer without their tumor growing back.

Current treatment options for recurrent brain tumors with these genetic mutations are limited, and many patients don't have good outcomes. This medication was designed to work in a specific way against these types of tumors, and early results suggest it may be more effective than existing treatments.

Do you qualify?

You likely qualify if…

you are at least 15 years old
you have been diagnosed with a recurrent brain tumor (glioma, WHO grades 2–4) with an IDH1 or IDH2 mutation confirmed by genetic testing
you have received previous treatment such as radiation therapy or chemotherapy before your tumor came back
you have a Karnofsky performance status score of 70% or higher (meaning you are fairly active and able to care for yourself)
your blood counts and organ function (liver, kidneys) are adequate for safe treatment
you are willing to use effective birth control during treatment and for 3 months after, if applicable

You likely don't qualify if…

you have had more than one tumor relapse (if your initial tumor was grade 3–4) or more than two relapses (if grade 2), for the Phase II portion of the trial
you have received certain chemotherapy drugs within the past 2–6 weeks before starting the trial
you had brain surgery within the past 2 weeks
you received radiation therapy to your brain within the past 30 days
you have previously been treated with bevacizumab (an antibody therapy) for your brain tumor

What participation looks like

You will take the medication by mouth on a regular schedule in 28-day cycles. The first phase of the trial will test different doses to find the safest and most effective amount. In the second phase, participants will take the recommended dose. Some participants may be asked to take one dose the day before brain surgery or a biopsy, then continue treatment afterward. You will have regular clinic visits, blood tests, and imaging scans to check how you are responding and monitor for side effects.

Testing a new medication for recurrent brain tumors with specific genetic mutations

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)